Complete Guide to Thyroid Conditions: Hypothyroidism, Hyperthyroidism, and Thyroid Nodules

How the Thyroid Gland Works

The thyroid gland is a butterfly-shaped organ located at the base of the neck, just below the larynx. Weighing approximately 20–30 grams in healthy adults, it is responsible for producing two iodine-containing hormones — thyroxine (T4) and triiodothyronine (T3) — that regulate metabolism, heart rate, body temperature, growth, and the function of nearly every organ in the body. Thyroid disease is extraordinarily common: the American Thyroid Association estimates that 20 million Americans have some form of thyroid disorder, and up to 60 percent of those affected are unaware of their condition.

The HPT Axis and Feedback Loop

Thyroid hormone production is governed by the hypothalamic-pituitary-thyroid (HPT) axis, a tightly regulated feedback system. The hypothalamus detects low circulating thyroid hormone levels and releases thyrotropin-releasing hormone (TRH). TRH signals the anterior pituitary to secrete thyroid-stimulating hormone (TSH). TSH then travels through the bloodstream to the thyroid gland, where it stimulates the synthesis and release of T4 and T3. As T4 and T3 rise, they feed back negatively on both the hypothalamus and the pituitary, suppressing TRH and TSH secretion and preventing overproduction.

This feedback architecture means that TSH is the most sensitive indicator of thyroid status. Even a small change in circulating thyroid hormone levels produces an amplified inverse change in TSH — a 2-fold change in free T4 is associated with a roughly 100-fold change in TSH in the opposite direction. This is why TSH is the first-line test for evaluating thyroid function in most clinical scenarios.

T4 vs T3: Production and Conversion

The thyroid secretes primarily T4 (approximately 80–90 percent of total output), which acts largely as a prohormone. T4 is converted peripherally — mostly in the liver, kidneys, and other tissues — to the biologically active T3 by enzymes called deiodinases. T3 is approximately 3–5 times more potent than T4 and is responsible for most of the downstream metabolic effects. About 20 percent of circulating T3 comes directly from the thyroid; the remaining 80 percent is derived from peripheral T4-to-T3 conversion.

In the blood, both T4 and T3 circulate mostly bound to carrier proteins — primarily thyroxine-binding globulin (TBG), transthyretin, and albumin. Only the unbound ("free") fraction — Free T4 (fT4) and Free T3 (fT3) — is biologically active. Laboratory testing of free hormone levels therefore provides a more accurate reflection of thyroid status than total hormone measurements, which can be misleading when protein-binding changes (e.g., pregnancy, oral contraceptive use, liver disease).

Normal TSH Reference Range

The conventional normal TSH range in most laboratories is 0.4–4.0 mIU/L, though some guidelines use 0.45–4.5 mIU/L. Important nuances include:

• Age adjustment: TSH naturally increases with age. A TSH of 4.5 mIU/L may be entirely normal in a 70-year-old but warrants further evaluation in a 30-year-old.
• Pregnancy-specific ranges: TSH targets differ by trimester (discussed in detail below).
• Population variation: Some large population studies suggest a more appropriate upper limit of normal may be 2.5 mIU/L, though this remains debated.

Use the TSH Interpreter to evaluate any TSH value in the context of clinical factors including age, symptoms, and concurrent free T4.

---

Hypothyroidism

Hypothyroidism — underactive thyroid — is one of the most prevalent endocrine disorders worldwide, affecting approximately 5 percent of the U.S. population aged 12 years and older, with higher prevalence in women and older adults. It results from insufficient thyroid hormone production to meet the body's metabolic demands.

Causes

The most common cause of hypothyroidism in iodine-sufficient countries is Hashimoto's thyroiditis (autoimmune thyroiditis), which accounts for roughly 90–95 percent of cases. Other causes include:

• Post-ablative hypothyroidism — following radioactive iodine (RAI) therapy or thyroidectomy for hyperthyroidism or thyroid cancer
• Iodine deficiency — the leading cause worldwide, particularly in developing nations
• Drug-induced hypothyroidism — lithium, amiodarone, interferon-alpha, tyrosine kinase inhibitors
• Central hypothyroidism — pituitary or hypothalamic disease causing TSH deficiency (rare; TSH may be normal or low despite low free T4)
• Congenital hypothyroidism — detected on newborn screening; affects approximately 1 in 2,000–4,000 births

Symptoms

Hypothyroidism reduces metabolic rate across all organ systems. Classic symptoms include:

• Metabolic: fatigue, cold intolerance, weight gain despite unchanged appetite, constipation
• Cardiovascular: bradycardia (slow heart rate), diastolic hypertension, elevated LDL cholesterol
• Neuromuscular: muscle cramps, weakness, delayed deep tendon reflex relaxation ("hung reflexes"), carpal tunnel syndrome
• Cognitive and psychiatric: impaired memory, slowed thinking, depression
• Dermatological: dry skin, hair loss, brittle nails, periorbital edema, myxedema (non-pitting edema in severe cases)
• Reproductive: menstrual irregularities, infertility, spontaneous abortion

Symptoms are often nonspecific and overlap with many other conditions, underscoring the importance of biochemical confirmation.

Diagnosis: TSH and Free T4 Thresholds

Primary hypothyroidism is diagnosed biochemically:

| TSH Level | Free T4 Level | Interpretation | |---|---|---| | >4.5 mIU/L | Below normal | Overt hypothyroidism | | >4.5 mIU/L | Normal | Subclinical hypothyroidism | | Normal (0.4–4.5) | Low | Central hypothyroidism (evaluate pituitary) | | Low | Low | Central hypothyroidism or recent treatment of hyperthyroidism |

When TSH is elevated, Free T4 should be measured to distinguish overt from subclinical disease. Anti-thyroid peroxidase antibodies (anti-TPO Ab) are positive in >90 percent of Hashimoto's thyroiditis cases and help confirm autoimmune etiology, though they are not required for diagnosis.

Hashimoto's Thyroiditis

Hashimoto's thyroiditis is a chronic autoimmune condition in which the immune system mounts an attack against thyroid tissue, leading to progressive destruction of thyroid follicles and eventual glandular fibrosis. It is the most common organ-specific autoimmune disease in the world.

Key features of Hashimoto's:

• Antibodies: Elevated anti-TPO antibodies (present in >90%) and/or anti-thyroglobulin antibodies. Anti-TPO titers do not directly predict symptom severity or treatment need — treatment is driven by TSH and fT4 levels.
• Ultrasound findings: Diffusely hypoechoic, heterogeneous thyroid parenchyma with a coarse "cobblestone" texture on ultrasound, often with reduced vascularity.
• Hashitoxicosis: In early disease, thyroid follicle destruction can transiently release stored hormone, causing a brief hyperthyroid phase ("hashitoxicosis") before hypothyroidism develops.
• Association with other autoimmune diseases: Hashimoto's is associated with type 1 diabetes, rheumatoid arthritis, Sjögren's syndrome, vitiligo, and celiac disease.
• Thyroid lymphoma: A rare but recognized complication; rapid gland enlargement warrants evaluation.

Treatment: Levothyroxine Dosing

Levothyroxine (L-thyroxine, LT4) is the standard treatment for hypothyroidism. It is a synthetic T4 that the body converts to active T3.

Standard dosing:

The typical full replacement dose is 1.6 mcg/kg/day of ideal body weight in adults with primary hypothyroidism. For a 70 kg individual, this approximates 112 mcg/day. Use the Thyroid Dose Calculator to calculate an individualized starting dose.

Dose adjustments:

• Older adults (>65 years): Start lower — 25–50 mcg/day — to avoid precipitating atrial fibrillation or angina. Titrate slowly.
• Coronary artery disease: Start at 12.5–25 mcg/day and increase cautiously every 4–6 weeks.
• Subclinical hypothyroidism (TSH 4.5–10 mIU/L): A lower starting dose (25–50 mcg/day) is often appropriate.
• Central hypothyroidism: Target free T4 in the upper half of the normal range rather than TSH.

Monitoring:

• Recheck TSH 6–8 weeks after initiating or changing levothyroxine; adjust dose in 12.5–25 mcg increments as needed.
• Once stable, annual TSH monitoring is standard.
• Consistent timing is critical — levothyroxine should be taken on an empty stomach, 30–60 minutes before breakfast, or at bedtime (at least 3 hours after the last meal).

Drug interactions reducing absorption:

Calcium supplements, iron supplements, proton pump inhibitors, cholestyramine, and antacids containing aluminum or magnesium all impair levothyroxine absorption. Separate these agents by at least 4 hours.

---

Hyperthyroidism

Hyperthyroidism — overactive thyroid — occurs when the thyroid produces excessive hormone, accelerating metabolism and creating a state of hyperadrenergic excess. It affects approximately 1.3 percent of the U.S. population, with a strong female predominance (5:1 to 10:1 female-to-male ratio).

Causes

• Graves' disease — accounts for 60–80 percent of all hyperthyroidism; an autoimmune condition caused by TSH receptor-stimulating antibodies (TRAb)
• Toxic multinodular goiter (TMNG) — multiple autonomously functioning thyroid nodules; more common in older adults and iodine-deficient regions
• Toxic adenoma (Plummer's disease) — single hyperfunctioning nodule
• Thyroiditis — subacute (de Quervain's), silent/painless (autoimmune), or postpartum; inflammation causes release of preformed hormone
• Iodine-induced hyperthyroidism (Jod-Basedow) — after iodine-containing contrast agents or amiodarone in those with underlying nodular disease
• Exogenous thyroid hormone excess — inadvertent or intentional over-replacement with levothyroxine

Symptoms

Hyperthyroidism mimics a hyperadrenergic state:

• Cardiovascular: palpitations, tachycardia, atrial fibrillation (particularly in older adults), wide pulse pressure, heart failure in severe cases
• Metabolic: heat intolerance, sweating, unexplained weight loss despite increased appetite, hyperdefecation
• Neuromuscular: tremor, proximal muscle weakness, hyperreflexia, myopathy
• Cognitive/psychiatric: anxiety, irritability, emotional lability, insomnia
• Ophthalmologic (Graves' specific): proptosis (exophthalmos), lid lag, periorbital edema, diplopia — known collectively as Graves' ophthalmopathy (thyroid eye disease)
• Dermatological: warm, moist skin; fine, thinning hair; pretibial myxedema (Graves'-specific dermopathy); thyroid acropachy

Diagnosis

A suppressed TSH (<0.4 mIU/L) with elevated Free T4 and/or Free T3 confirms overt hyperthyroidism. When TSH is suppressed but free hormones are normal, subclinical hyperthyroidism is diagnosed.

Distinguishing the cause:

• TSH receptor antibodies (TRAb or TSI): Positive in >95% of active Graves' disease; the most specific test for Graves'.
• Radioactive iodine uptake (RAIU) scan: Diffusely elevated uptake in Graves', patchy in TMNG, reduced or absent in thyroiditis. Not needed when TRAb is positive and clinical presentation is classic.
• Thyroid ultrasound with Doppler: Marked hypervascularity ("thyroid inferno") in Graves'; nodular pattern in TMNG.

Treatment Options

1. Antithyroid drugs (ATDs):

• Methimazole is the preferred ATD in most patients; typical starting dose 10–30 mg/day depending on severity, titrated to maintain euthyroidism.
• Propylthiouracil (PTU) is reserved for: first trimester of pregnancy (methimazole is teratogenic in T1), thyroid storm, and patients with methimazole intolerance.
• ATDs inhibit thyroid peroxidase, blocking hormone synthesis. A 12–18 month course achieves remission in approximately 30–50 percent of Graves' disease patients.
• Major side effects: agranulocytosis (0.2–0.5%; patients should immediately stop the drug and seek evaluation for fever, sore throat), hepatotoxicity (PTU > methimazole), ANCA-associated vasculitis (PTU).

2. Radioactive iodine (RAI) ablation:

RAI (I-131) is absorbed by thyroid tissue and destroys thyroid cells, inducing hypothyroidism in most patients over 6–18 months. It is effective, safe, and the most widely used definitive treatment in the U.S. Contraindicated in pregnancy and breastfeeding, and used cautiously in those with moderate-to-severe Graves' ophthalmopathy (may worsen eye disease unless glucocorticoids are co-administered).

3. Thyroidectomy:

Surgery offers immediate definitive control and is preferred when: the goiter is large or obstructive, malignancy is suspected, patient is pregnant and ATDs fail, or the patient prefers it. Subtotal or total thyroidectomy results in permanent hypothyroidism requiring lifelong levothyroxine therapy.

4. Beta-blockers (symptomatic relief):

Propranolol (10–40 mg every 6–8 hours) or atenolol controls adrenergic symptoms — tachycardia, tremor, anxiety — while waiting for ATDs to take effect (typically 4–8 weeks). Beta-blockers do not reduce thyroid hormone production.

Thyroid Storm

Thyroid storm is a life-threatening hypermetabolic emergency in which extreme hyperthyroidism causes multi-organ dysfunction. It carries a mortality rate of 10–30 percent even with treatment. Burch-Wartofsky criteria are used for clinical scoring (score ≥45 points = highly likely thyroid storm).

Clinical features:

• Hyperthermia (often >40°C / 104°F)
• Severe tachycardia or atrial fibrillation
• Altered mental status (agitation, delirium, coma)
• Congestive heart failure
• Nausea, vomiting, diarrhea, jaundice

Emergency management (the "4 Ts" plus steroids):

1. PTU — 500–1000 mg loading dose, then 250 mg every 4 hours; blocks both synthesis and peripheral T4-to-T3 conversion
2. Potassium iodide or Lugol's solution — given at least 1 hour after PTU to block thyroid hormone release via the Wolff-Chaikoff effect
3. Hydrocortisone 300 mg IV bolus then 100 mg every 8 hours — reduces T4-to-T3 conversion and addresses potential relative adrenal insufficiency
4. Propranolol IV or high-dose oral — controls adrenergic symptoms and reduces T4-to-T3 conversion
5. Supportive care — IV fluids, cooling blankets, ICU monitoring

---

Subclinical Thyroid Disease

Subclinical thyroid disorders are defined by abnormal TSH with normal free T4 and free T3 levels. They are common, particularly in older adults, and the decision to treat requires individualized risk-benefit analysis.

Subclinical Hypothyroidism

Defined as TSH >4.5 mIU/L with a normal free T4. Prevalence is approximately 3–8 percent of the general population and 10–15 percent in women over age 60.

When to treat:

• TSH >10 mIU/L: Most guidelines (ATA, ETA) recommend treatment regardless of symptoms, due to increased cardiovascular risk and risk of progression to overt hypothyroidism.
• TSH 4.5–10 mIU/L with symptoms attributable to hypothyroidism: Treatment with a trial of levothyroxine is reasonable; reassess at 6 months.
• TSH 4.5–10 mIU/L, asymptomatic, age >65–70: Evidence for treatment benefit is weak; observational studies suggest watchful waiting is appropriate in many older adults. Risks of over-treatment (atrial fibrillation, bone loss) must be weighed.
• Pregnancy: Treatment is recommended when TSH exceeds trimester-specific thresholds (see below).

Subclinical Hyperthyroidism

Defined as TSH <0.4 mIU/L with normal free T4 and free T3. Prevalence is approximately 0.7 percent in iodine-sufficient populations.

TSH gradations and clinical significance:

| TSH (mIU/L) | Category | Clinical Significance | |---|---|---| | 0.1–0.4 | Mild subclinical hyperthyroidism | Lower cardiovascular risk; often observe | | <0.1 | Moderate subclinical hyperthyroidism | Increased AF risk; consider treatment if persistent | | <0.01 | Severe subclinical hyperthyroidism | Treat: AF, bone loss risk equivalent to overt disease |

Consequences of untreated subclinical hyperthyroidism:

• Atrial fibrillation: TSH <0.1 mIU/L is associated with a 3-fold increased risk of atrial fibrillation.
• Bone loss: Particularly in postmenopausal women; equivalent fracture risk to overt hyperthyroidism at severe suppression.
• Cardiovascular mortality: Meta-analyses show increased cardiovascular mortality with TSH <0.1 mIU/L, particularly in those >65 years.

---

Thyroid Nodules

Thyroid nodules are extraordinarily common. High-resolution ultrasound detects nodules in 19–68 percent of adults, with higher prevalence in women and older age groups. However, the vast majority are benign — thyroid cancer is found in only 7–15 percent of biopsied nodules.

Initial Evaluation

All thyroid nodules are evaluated with:

1. Thyroid ultrasound: Characterizes nodule size, echogenicity, borders, internal composition (solid vs. cystic), calcifications, and vascularity.
2. TSH measurement: If TSH is suppressed, a radionuclide (technetium or I-123) thyroid scan is obtained to determine if the nodule is "hot" (hyperfunctioning — almost never malignant) or "cold" (euthyroid/nonfunctioning — standard malignancy workup applies).
3. Fine needle aspiration (FNA) biopsy: The primary diagnostic tool for evaluating malignancy risk when ultrasound features and size meet biopsy criteria.

ACR TIRADS Classification

The American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) assigns points across five ultrasound feature categories — composition, echogenicity, shape, margin, and echogenic foci — to generate a risk score:

| TI-RADS Level | Points | Risk | FNA Threshold | |---|---|---|---| | TR1 | 0 | Benign | No FNA | | TR2 | 2 | Not suspicious | No FNA | | TR3 | 3 | Mildly suspicious | FNA if ≥2.5 cm | | TR4 | 4–6 | Moderately suspicious | FNA if ≥1.5 cm | | TR5 | ≥7 | Highly suspicious | FNA if ≥1.0 cm |

Features raising suspicion include: hypoechoic or markedly hypoechoic composition, taller-than-wide shape, irregular or lobulated margin, and microcalcifications. Purely cystic nodules are almost always benign and do not require FNA regardless of size.

Bethesda Classification of FNA Results

The Bethesda System for Reporting Thyroid Cytopathology provides a standardized framework for FNA interpretation with associated malignancy risks:

| Bethesda Category | Description | Malignancy Risk | Recommended Action | |---|---|---|---| | I | Non-diagnostic/unsatisfactory | 5–10% | Repeat FNA | | II | Benign | 0–3% | Clinical follow-up | | III | Atypia of undetermined significance (AUS/FLUS) | 6–18% | Repeat FNA or molecular testing | | IV | Follicular neoplasm | 10–40% | Lobectomy or molecular testing | | V | Suspicious for malignancy | 45–75% | Near-total thyroidectomy | | VI | Malignant | 94–96% | Near-total thyroidectomy |

Molecular testing (e.g., Afirma Gene Sequencing Classifier, ThyroSeq) is increasingly used for Bethesda III/IV nodules to help guide surgical decision-making by reclassifying indeterminate cytology results.

Which Nodules to Watch vs. Biopsy

No biopsy needed:

• TR1–TR2 nodules of any size
• TR3 nodules <2.5 cm
• Purely cystic nodules
• Incidentally discovered nodules in patients undergoing PET scan with no high-risk features (note: PET-avid thyroid nodules do carry increased malignancy risk and should be evaluated)

Surveillance protocol for benign nodules:

• Repeat ultrasound at 12–24 months; if stable, extend to every 3–5 years
• Significant growth (≥20% increase in at least 2 dimensions) or new suspicious features should prompt repeat FNA

---

Thyroid Cancer

Thyroid cancer is the most common endocrine malignancy, with approximately 44,000 new cases diagnosed annually in the U.S. The incidence has been rising primarily due to detection of small papillary cancers on incidental imaging. Fortunately, the overall prognosis is excellent — the 5-year survival rate for differentiated thyroid cancer exceeds 98 percent.

Types of Thyroid Cancer

Papillary thyroid cancer (PTC)

• 80–85 percent of all thyroid cancers
• Excellent prognosis; 5-year survival >99% for localized disease
• Pathological hallmarks: Orphan Annie eye nuclei, nuclear grooves, psammoma bodies
• Common metastatic routes: cervical lymph nodes (40–80% of cases, but does not necessarily worsen prognosis), rare distant metastases

Follicular thyroid cancer (FTC)

• 10–15 percent of thyroid cancers
• Cannot be distinguished from follicular adenoma on FNA; diagnosis requires histological evidence of capsular or vascular invasion
• More likely to spread hematogenously (to lung, bone, brain) than PTC

Medullary thyroid cancer (MTC)

• 3–5 percent of thyroid cancers
• Arises from parafollicular C-cells (calcitonin-producing); not differentiated thyroid cancer
• 25 percent hereditary (associated with MEN2A, MEN2B, or familial MTC); all patients require RET proto-oncogene testing
• Marked by elevated serum calcitonin and carcinoembryonic antigen (CEA)
• Does NOT concentrate iodine; RAI ablation is not effective

Anaplastic thyroid cancer (ATC)

• <2 percent of thyroid cancers; highly aggressive
• Almost always fatal; median survival 3–5 months from diagnosis
• Often requires multidisciplinary approach; BRAF V600E mutation present in ~50%; targeted therapy with dabrafenib/trametinib approved for BRAF-mutated ATC

Staging and Prognosis

The AJCC 8th Edition staging system changed significantly in 2018: all differentiated thyroid cancers in patients under age 55 are classified as Stage I or II (regardless of metastases), reflecting the excellent prognosis of younger patients. Age 55 remains the critical cut-off for staging purposes.

RAI Ablation

Post-surgical radioactive iodine (RAI, I-131) ablation is used selectively in differentiated thyroid cancers to destroy residual thyroid tissue, facilitate monitoring via thyroglobulin, and treat iodine-avid metastases. It is:

• Recommended: For high-risk tumors (>4 cm, extrathyroidal extension, distant metastases)
• Selectively used: For intermediate-risk tumors based on surgical and pathological findings
• Not recommended: For most low-risk tumors (intrathyroidal PTC <4 cm, no aggressive features)

RAI is administered after thyroid hormone withdrawal or recombinant TSH (Thyrogen) stimulation to maximize I-131 uptake by residual thyroid/tumor tissue.

Long-Term Monitoring

After treatment for differentiated thyroid cancer, monitoring relies on:

• Serum thyroglobulin (Tg): A tumor marker produced by thyroid/cancer tissue; should be undetectable after total thyroidectomy and RAI ablation
• Anti-thyroglobulin antibodies (TgAb): Interfere with Tg assays; must be trended independently
• Neck ultrasound: Every 6–12 months for the first 5 years
• TSH suppression therapy: For high-risk cancer, levothyroxine is dosed to maintain TSH <0.1 mIU/L; for low-risk disease, TSH is maintained in the low-normal range (0.5–2.0 mIU/L)

---

Thyroid Disease in Pregnancy

Thyroid disorders are among the most common medical conditions complicating pregnancy, and both untreated hypothyroidism and hyperthyroidism carry significant risks to maternal and fetal health. The physiological changes of pregnancy profoundly alter thyroid function tests, making pregnancy-specific reference ranges essential.

Physiological Changes in Pregnancy

• Increased TBG: Estrogen increases hepatic TBG production, raising total T4 and T3 levels; free hormone levels are less affected but can be artificially low with certain assay methods.
• hCG-mediated TSH suppression: Human chorionic gonadotropin (hCG), which peaks at 10–12 weeks, shares structural homology with TSH and stimulates the TSH receptor, mildly suppressing TSH in the first trimester.
• Increased iodine requirement: Renal iodine clearance increases ~50% during pregnancy; the WHO recommends 250 mcg iodine daily for pregnant and breastfeeding women (vs. 150 mcg for non-pregnant adults).
• Increased thyroid hormone demand: Peripheral metabolism of thyroid hormones increases and the fetus relies on maternal thyroid hormones (particularly T4) for brain development until 18–20 weeks, when the fetal thyroid becomes functional.

TSH Targets by Trimester

| Trimester | Recommended TSH Target (ATA 2017) | |---|---| | First (1–12 weeks) | <2.5 mIU/L (some guidelines: lower limit of population-specific range) | | Second (13–26 weeks) | <3.0 mIU/L | | Third (27–40 weeks) | <3.0 mIU/L |

Key clinical implications:

• Levothyroxine dose requirements typically increase 25–50% during pregnancy (often from the first weeks), particularly in women with reduced or absent thyroid reserve (post-thyroidectomy, Hashimoto's, prior RAI).
• Women known to have hypothyroidism who are planning pregnancy should optimize TSH to <2.5 mIU/L prior to conception.
• Women on levothyroxine who discover pregnancy should increase their dose by approximately 30% immediately (e.g., add 2 extra doses per week) and contact their physician for monitoring.
• Uncontrolled hypothyroidism in pregnancy is associated with miscarriage, preeclampsia, preterm delivery, placental abruption, and impaired fetal neurodevelopment.

Hypothyroidism in Pregnancy: Treatment

Overt hypothyroidism: Treat immediately with levothyroxine; goal TSH in trimester-appropriate range. Monitor TSH every 4 weeks in the first trimester, then at least once each trimester.

Subclinical hypothyroidism with positive anti-TPO antibodies: ATA 2017 recommends levothyroxine treatment when TSH >2.5 mIU/L.

Subclinical hypothyroidism with negative anti-TPO antibodies: Treatment is suggested when TSH >4.0 mIU/L by ATA, though evidence for benefit at lower thresholds remains limited.

Hyperthyroidism in Pregnancy: Gestational vs. Graves'

Gestational transient thyrotoxicosis (GTT): Caused by hCG stimulation, typically resolves by 14–18 weeks. TSH is suppressed but free T4 is only mildly elevated; often associated with hyperemesis gravidarum. Does not require antithyroid drugs — supportive care only.

Graves' disease in pregnancy: Requires treatment to prevent maternal and fetal complications including: fetal growth restriction, preterm delivery, fetal thyrotoxicosis (TSH receptor antibodies cross the placenta), and neonatal hyperthyroidism.

• First trimester: PTU is preferred (methimazole is associated with embryopathy including choanal atresia and aplasia cutis in the first trimester)
• Second and third trimesters: Switch to methimazole (lower risk of PTU hepatotoxicity)
• Goal: Maintain maternal Free T4 in the upper third of the normal range using the lowest effective ATD dose

Postpartum Thyroiditis

Postpartum thyroiditis (PPT) is an autoimmune thyroid inflammation occurring in 5–10 percent of women within the first year after delivery, particularly in those with positive anti-TPO antibodies (risk ~50%). It typically follows a triphasic pattern:

1. Hyperthyroid phase (1–4 months postpartum): Mild, often asymptomatic; lasts 1–3 months; treat symptomatically with beta-blockers if needed (antithyroid drugs are ineffective as hormone release, not overproduction, is the mechanism)
2. Hypothyroid phase (4–8 months postpartum): More symptomatic; may require temporary levothyroxine therapy, particularly in breastfeeding women or those experiencing significant symptoms
3. Recovery phase: ~80% of women recover euthyroid function within 12 months; however, 25–30% develop permanent hypothyroidism within 5 years

---

Using the TSH Interpreter and Thyroid Dose Calculator

The TSH Interpreter on OnlineMedicalTools translates a TSH result into a clinically actionable interpretation, accounting for:

• Age-adjusted reference ranges
• Free T4 correlation
• Clinical context (overt vs. subclinical)
• Whether the result reflects treated or untreated disease
• Special populations (pregnancy, older adults)

The Thyroid Dose Calculator provides evidence-based levothyroxine starting and replacement dose recommendations based on:

• Patient weight (1.6 mcg/kg/day full replacement; reduced for subclinical or elderly)
• Clinical indication (overt hypothyroidism, subclinical hypothyroidism, thyroid cancer TSH suppression)
• Special considerations (pregnancy, heart disease, advanced age)

Both tools are designed to support clinical reasoning — results should always be interpreted in the context of the full clinical picture by a qualified healthcare provider.

---

Frequently Asked Questions

What is a normal TSH level?

For most adults, normal TSH ranges from approximately 0.4 to 4.0–4.5 mIU/L. However, this range should be interpreted in context. Older adults naturally have higher TSH; a value of 4.5 mIU/L in a healthy 75-year-old is unlikely to be clinically significant. Pregnant women have lower TSH targets by trimester (under 2.5 mIU/L in the first trimester). The TSH Interpreter helps apply age- and context-adjusted interpretation.

What is the difference between T4 and T3?

T4 (thyroxine) is the primary hormone secreted by the thyroid gland. It acts mainly as a prohormone and is converted to the biologically active T3 (triiodothyronine) in peripheral tissues by deiodinase enzymes. T3 is approximately 3–5 times more potent than T4 and is responsible for most thyroid hormone effects at the cellular level. Standard levothyroxine therapy replaces T4; in most patients, normal T4-to-T3 conversion provides adequate T3 levels.

When is the best time to take levothyroxine?

Levothyroxine is optimally absorbed when taken on an empty stomach — ideally 30–60 minutes before breakfast, or at bedtime (at least 3–4 hours after the last meal). Absorption is impaired by food (particularly high-fiber foods, coffee), and by calcium supplements, iron supplements, antacids, proton pump inhibitors, and cholestyramine. Separating these agents by at least 4 hours maximizes absorption consistency.

Does diet affect Hashimoto's thyroiditis?

Iodine: Excess iodine can exacerbate Hashimoto's; moderate iodine intake (from dietary sources) is appropriate, but megadose iodine supplements should be avoided.

Gluten: There is a well-established association between Hashimoto's and celiac disease. In patients with both conditions, a gluten-free diet is recommended for celiac disease management; evidence that a gluten-free diet independently improves thyroid antibody levels or function in Hashimoto's patients without celiac disease is limited.

Selenium: Selenium (200 mcg/day) has been shown in randomized trials to reduce anti-TPO antibody titers over 12 months and may modestly improve quality of life in some patients. It does not replace levothyroxine therapy.

Soy and goitrogens: Large amounts of raw cruciferous vegetables and soy products may modestly interfere with thyroid hormone synthesis; dietary amounts are not clinically significant for most patients with adequately replaced hypothyroidism.

What TSH level requires levothyroxine treatment?

Overt hypothyroidism (TSH >4.5 mIU/L with low free T4) universally requires treatment. For subclinical hypothyroidism (TSH >4.5 mIU/L, normal free T4), most guidelines recommend treatment when TSH >10 mIU/L. For TSH 4.5–10 mIU/L, treatment decisions depend on symptoms, anti-TPO antibody status, pregnancy status, age, and cardiovascular risk factors.

Can hypothyroidism cause weight gain?

Yes, but typically modestly — 5–10 lbs in most cases, primarily due to salt and water retention (myxedema), not fat accumulation. Extreme weight gain (>20 lbs) is rarely attributable solely to hypothyroidism. Successful thyroid hormone replacement normalizes metabolism but does not always produce the dramatic weight loss patients expect, particularly if significant lifestyle factors are also present.

What is the risk of thyroid cancer in a thyroid nodule?

The overall risk of malignancy in a thyroid nodule referred for FNA biopsy is approximately 7–15 percent. Risk depends heavily on ultrasound features. Highly suspicious features on ACR TI-RADS (markedly hypoechoic, taller-than-wide, irregular margins, microcalcifications) carry a malignancy rate of 70–90 percent in biopsied nodules, while nodules with benign features (purely cystic, spongiform) are almost always benign.

When should I see an endocrinologist?

Consider referral to an endocrinologist for: newly diagnosed thyroid cancer or a suspicious thyroid nodule, hyperthyroidism of any cause, poorly controlled hypothyroidism despite optimal levothyroxine dosing, thyroid disease in pregnancy, thyroid storm, and Graves' ophthalmopathy. Stable, well-controlled hypothyroidism on levothyroxine can typically be managed by a primary care provider with annual TSH monitoring.

What is subclinical hypothyroidism?

Subclinical hypothyroidism is defined as an elevated TSH (above the laboratory upper limit of normal, typically >4.5 mIU/L) with normal free T4 and free T3 levels. Symptoms may be absent or subtle. The condition is especially common in women over 60. Whether to treat depends on the TSH level, symptom burden, anti-TPO antibody status, age, and cardiovascular risk — a nuanced decision best made collaboratively with a physician.

Is Graves' disease curable?

Graves' disease can achieve long-term remission. Antithyroid drug treatment induces remission in approximately 30–50 percent of patients after 12–18 months; remission is more likely in patients with small goiters, mild biochemical hyperthyroidism, negative TRAb at end of treatment, and female sex. Radioactive iodine and thyroidectomy are both highly effective definitive treatments that cure hyperthyroidism but result in permanent hypothyroidism requiring lifelong levothyroxine replacement.

---

This guide is intended for educational purposes only. TSH results, thyroid diagnoses, and treatment decisions should always be interpreted and made by a qualified healthcare provider in the context of a full clinical evaluation. Use the TSH Interpreter and Thyroid Dose Calculator as decision-support tools, not substitutes for medical advice.